A New Era in Oncology! Alvotech & Dr. Reddy’s Develop Cost-Effective Keytruda Alternative

Unknown Apr 02, 2026 1,600 Views

Alvotech SA, a leading global biotech firm specializing in biosimilars, and Dr. Reddy’s Laboratories, one of India’s top pharmaceutical companies, have entered into a strategic collaboration to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizuma...

Key Highlights of the Collaboration

Joint Development & Cost Sharing – Both companies will be equally responsible for developing and manufacturing the biosimilar candidate, ensuring cost-effective access to critical cancer treatments.
Global Commercialization Rights – Subject to certain exceptions, each party will have the right to market the biosimilar globally, expanding oncology treatment accessibility.
Keytruda’s Market Impact – In 2024, Keytruda generated $29.5 billion in global sales, making it one of the most widely used immuno-oncology drugs.
Industry Leaders Speak – Erez Israeli, CEO of Dr. Reddy’s, emphasized that oncology remains a top priority, while Robert Wessman, CEO of Alvotech, highlighted the importance of biosimilars in expanding global healthcare access.

Why This Collaboration Matters

Keytruda (pembrolizumab) is a monoclonal antibody that works by blocking the PD-1 protein, allowing the immune system to attack cancer cells more effectively. It is used to treat lung cancer, melanoma, head and neck cancer, and other malignancies.

With the high cost of biologic drugs, biosimilars offer a more affordable alternative, making life-saving treatments accessible to a broader patient population. The partnership between Alvotech and Dr. Reddy’s aims to accelerate biosimilar development, ensuring global availability of cost-effective cancer therapies.

Outlook on Biosimilars & Cancer Treatment

With biosimilars revolutionizing cancer treatment, this collaboration marks a significant step toward making immuno-oncology therapies more accessible worldwide. Experts predict that biosimilars will play a crucial role in reducing healthcare costs while maintaining high-quality treatment standards.

Sources: The Hindu, The Hindu BusinessLine, Financial Express, MSN, Dr. Reddy’s official statement.

Stay Ahead – Explore Now! Hitachi Energy India Announces INR 20 Billion Investment for New Transformer Factory in Vadodara